Clinical Hematology International

<Previous Article In Issue
Next Article In Issue>
Volume 1, Issue 3, September 2019, Pages 134 - 141

Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies

Authors
Ugur Sahin1, Meral Beksac2, *
1Hematology Unit, Yenimahalle Education and Research Hospital, Yildirim Beyazit University, Ankara, Turkey
2Department of Hematology, Faculty of Medicine, Ankara University, Cebeci Hospital, 06220, Ankara, Turkey
*Corresponding author. Ph.: +90 312 5957443; Fax: +90 312 3196062. Email: mbeksac56@gmail.com, Meral.Beksac@medicine.ankara.edu.tr
Corresponding Author
Meral Beksac
Received 18 March 2019, Accepted 20 June 2019, Available Online 1 September 2019.
DOI
10.2991/chi.d.190623.001How to use a DOI?
Keywords
Natural killer cells; Immuno-therapy; Hematological malignancies
Abstract

Our understanding on the mechanisms of graft versus tumor/leukemia (GvT/GvL) and graft versus host (GvH) effects has tremendously evolved within the past decades. During the search for a mechanism that augments GvT/GvL without increasing GvH effects, natural killer (NK) cells have clearly attracted attention. Current approaches of NK cell immunotherapy for hematological malignancies involve using methods for in vivo potentiation of NK cell proliferation and activity; adoptive transfer of NK cells from autologous and allogeneic sources [cord blood mononuclear cells, peripheral blood mononuclear cells, CD34+ stem cells] and NK cell lines; and genetic modification of NK cells. Several cytokines, including interleukin-2 and interleukin-15 take part in the development of NK cells and have been shown to boost NK cell effects both in vivo and ex vivo. Monoclonal antibodies directed towards certain targets, including stimulating CD16, blockade of NK cell receptors, and redirection of cytotoxicity to tumor cells via bi- or tri-specific engagers may promote NK cell function. Despite the relative disappointment with autologous NK cell infusions, the future holds promise in adoptive transfer of allogeneic NK cells and the development of novel cellular therapeutic strategies, such as chimeric antigen receptor-modified NK cell immunotherapy. In this review, we summarize the current status of NK cell-related mechanisms in the therapy of hematologic malignancies, and discuss the future perspectives on adoptive NK cell transfer and other novel cellular immunotherapeutic strategies.

Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

<Previous Article In Issue
Next Article In Issue>
Journal
Clinical Hematology International
Volume-Issue
1 - 3
Pages
134 - 141
Publication Date
2019/09/01
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.190623.001How to use a DOI?
Copyright
© 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

risenwbib
TY  - JOUR
AU  - Ugur Sahin
AU  - Meral Beksac
PY  - 2019
DA  - 2019/09/01
TI  - Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies
JO  - Clinical Hematology International
SP  - 134
EP  - 141
VL  - 1
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.190623.001
DO  - 10.2991/chi.d.190623.001
ID  - Sahin2019
ER  -